Back to Catalog
PURITY VERIFIED
MechanismTriple GIP/GLP-1/Glucagon receptor agonist
FormInjectable
Purity≥98% HPLC
Peptides
Retatrutide
Retatrutide is an investigational triple-hormone receptor agonist (GIP, GLP-1, and glucagon) developed by Eli Lilly for research in obesity and type 2 diabetes. Known as a 'triple-G' agonist, it significantly reduces appetite and body weight.
Analytical Batch Options
In Stock & Verified
5mg / 10 vialsBATCH: RT5
$100 USD
10mg / 10 vialsBATCH: RT10
$120 USD
15mg / 10 vialsBATCH: RT15
$180 USD
20mg / 10 vialsBATCH: RT20
$210 USD
30mg / 10 vialsBATCH: RT30
$250 USD
Validated Research Areas
ObesityType 2 DiabetesMetabolic Research
Notice for Investigators
This compound is supplied exclusively for internal laboratory research by qualified professional personnel. It is not for human therapeutic or diagnostic administration. Compliance with local regulatory guidelines is the sole responsibility of the investigator.